Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 16/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | AXL | P30530 | 1/20 | 0.30 |
| ▸ | MERTK | Q12866 | 1/20 | 0.30 |
| ▸ | GBA1 | P04062 | 1/20 | 0.30 |
| ▸ | UGCG | Q16739 | 1/20 | 0.30 |
| ▸ | GBA2 | Q9HCG7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4883249 | 1.00 | REN (0.42) | RENHTR1ASLC6A4AXLMERTK | |
| SCHEMBL2341355 | 0.93 | REN (0.44) | RENHTR1ASLC6A4 | |
| SCHEMBL8498638 | 0.93 | REN (0.44) | RENHTR1ASLC6A4 | |
| SCHEMBL14257449 | 0.90 | REN (0.38) | REN | |
| SCHEMBL2339846 | 0.90 | REN (0.38) | REN | |
| SCHEMBL2340323 | 0.90 | REN (0.45) | REN | |
| SCHEMBL14257433 | 0.90 | REN (0.45) | REN | |
| SCHEMBL1036574 | 0.90 | REN (0.47) | RENGBA1UGCGGBA2 | |
| SCHEMBL2340846 | 0.90 | REN (0.42) | RENAXLMERTKGBA1UGCG | |
| SCHEMBL8486336 | 0.90 | REN (0.42) | RENAXLMERTKGBA1UGCG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2163245-A1 | Renin inhibitors for the treatment of psoriasis | Novartis Ag (CH) | 2010-03-17 | — | — | EP | disclosed |
| US-20080076766-A1 | Piperidine Derivatives As Renin Inhibitor | SPEEDEL EXPERIMENTA AG (CH) | 2008-03-27 | — | — | US | disclosed |
| US-20080076766-A1 | Piperidine Derivatives As Renin Inhibitor | SPEEDEL EXPERIMENTA AG (CH) | 2008-03-27 | — | — | US | disclosed |
| US-20070167433-A1 | 3,4,5-Substituted piperidines as therapeutic compounds | SPEEDEL EXPERIMENTA AG (CH) | 2007-07-19 | — | — | US | disclosed |
| US-20070167433-A1 | 3,4,5-Substituted piperidines as therapeutic compounds | SPEEDEL EXPERIMENTA AG (CH) | 2007-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076766-A1 | Piperidine Derivatives As Renin Inhibitor | REN, AGTR1, ACE | REN 1/4885HTR1A 2240/4885SLC6A4 2449/4885 |
| US-20070167433-A1 | 3,4,5-Substituted piperidines as therapeutic compounds | CTSD, CTSL, CTSZ | REN 119/4885HTR1A 3141/4885SLC6A4 2579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.